# Zenshine

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/zenshine

- Industry: Pharmaceuticals
- Headquarters: Nanjing, China
- Website: www.zenshine-pharma.com
- Total disclosed funding: $80M
- Latest round: Series C (Oct 13, 2023)
- Investors on record: 14

## About

Founded in 2018 and based in Nanjing, China, Zenshine is a biopharmaceutical company that focuses on the research and development of new small molecule drugs for cancer, viral infection and autoimmune diseases. In 2020, the company's innovative drug ZX-101A was approved by the US FDA for clinical trials. Jinfu Yang, co-founder and chairman of the company, has worked in biotech companies such as Cytokinetics, Proteolix and Calithera as a scientist, deputy director and director. The company has branches in cities such as Beijing and Hangzhou. In October 2025, Zenshine closed a venture funding from returning investors Zbjl Capital and Ennovation Ventures, with participation from new investors China Capital Management, In Capital, Jingjie Investment, Proxima Ventures, Proxima Ventures, Tailong VC and an individuals investor.

The company's R&D pipeline includes best-in-class and first-in-class drug molecules. Its main products include ZX-4081, ZX-101A, ZX-7101A and ZX-3000 etc. The company's products are used for diseases such as influenza, tumors, and hematomas.

The company generates revenue by doing research, development and providing biopharmaceutical and other related products and services.

## Funding rounds

- Series C, Oct 13, 2023, $14M — Cybernaut Investment Group, Kunlun, Shenzhen Co-way Capital, Jumpcan Pharmaceutical
- Series B, Mar 11, 2023, $15M — Cybernaut Investment Group, MPC, Hankang Capital, Ennovation Ventures, Yangzijiang Fund
- Series A, Jun 6, 2021, $31M — MPC, CS Capital, Lyzz Capital
- Series A, Jan 29, 2021, $15M — Jiuyo Capital, Fengling Capital, Jiangsu Dingzhu Technology, Indaco Capital
- Angel, Jun 22, 2018, $4.9M — Ennovation Ventures

## Investors

- Ennovation Ventures (https://capitalatlas.ai/funds/ennovation-ventures) — Angel, Series B
- Jiuyo Capital (https://capitalatlas.ai/funds/jiuyo-capital) — Series A
- Fengling Capital — Series A
- Jiangsu Dingzhu Technology — Series A
- Indaco Capital (https://capitalatlas.ai/funds/indaco-capital) — Series A
- MPC — Series A, Series B
- CS Capital — Series A
- Lyzz Capital (https://capitalatlas.ai/funds/lyzz-capital) — Series A
- Cybernaut Investment Group (https://capitalatlas.ai/funds/cybernaut-investment-group) — Series B, Series C
- Hankang Capital (https://capitalatlas.ai/funds/hankang-capital) — Series B
- Yangzijiang Fund (https://capitalatlas.ai/funds/yangzijiang-fund) — Series B
- Kunlun (https://capitalatlas.ai/funds/kunlun) — Series C
- Shenzhen Co-way Capital (https://capitalatlas.ai/funds/shenzhen-co-way-capital) — Series C
- Jumpcan Pharmaceutical — Series C